Category Pharma/Biotech

Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment…

Read MoreJemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received written notification from NYSE American LLC (“NYSE…

Read MoreNavidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297). ALTAIR is the circulating…

Read MoreNatera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer

Global Adult Vaccine Market Projected to Reach $27.65 Billion by 2028 with a Strong CAGR of 6.01% During 2023-2028 – ResearchAndMarkets.com

The global adult vaccine market is expected to witness substantial growth, reaching a projected value of US$ 27.65 Billion by 2028, with a strong compound annual growth rate (CAGR) of…

Read MoreGlobal Adult Vaccine Market Projected to Reach $27.65 Billion by 2028 with a Strong CAGR of 6.01% During 2023-2028 – ResearchAndMarkets.com

End Drug Shortages Alliance Recommends Specific Actions to Mitigate Drug Shortages in Wake of Damage to Pfizer Plant in North Carolina

The End Drug Shortage Alliance, today announced recommended actions healthcare industry stakeholders should immediately take to help minimize supply chain disruptions of sterile injectable medications in the wake of the tornado…

Read MoreEnd Drug Shortages Alliance Recommends Specific Actions to Mitigate Drug Shortages in Wake of Damage to Pfizer Plant in North Carolina

Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends Kernel, a leader in…

Read MoreCybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Pioneering Technologies in Minimally Invasive Surgery by Topcon Corporation, Olympus Corporation, and Leica Microsystems Propel Growth in Global Surgical Stapling Devices Market – ResearchAndMarkets.com

The “Surgical Stapling Devices Market Size, Share & Trends Analysis Report By Product (Powered, Manual), By Type (Disposable, Reusable), By End-use (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2023…

Read MorePioneering Technologies in Minimally Invasive Surgery by Topcon Corporation, Olympus Corporation, and Leica Microsystems Propel Growth in Global Surgical Stapling Devices Market – ResearchAndMarkets.com